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to reduce smoking-related 
neutrophilic inflammation
David CL Lam1, Stanley CH Chan1,2, Judith CW Mak1,3, Craig Freeman4, Mary SM Ip1 & 
Daisy KY Shum2
Cigarette smoke induces injury and neutrophilic inflammation in the airways of smokers. The 
stability and activity of inflammatory effectors, IL8 and neutrophil elastase (NE), can be prolonged 
by binding to airway heparan sulfate (HS)/syndecan-1, posing risk for developing chronic obstructive 
pulmonary disease(COPD). We hypothesize that antagonizing HS/syndecan-1 binding of the 
inflammatory effectors could reduce smoking-related neutrophil-mediated airway inflammation. 
Analysis of bronchoalveolar lavage fluid(BALF) of COPD patients found both total and unopposed 
NE levels to be significantly higher among smokers with COPD than non-COPD subjects. Similar 
NE burden was observed in smoke-exposed rats compared to sham air controls. We chose sulfated-
maltoheptaose(SM), a heparin-mimetic, to antagonize HS/sydecan-1 binding of the inflammatory 
mediators in airway fluids and lung tissues of the smoke-exposed rat model. Airway treatment 
with SM resulted in displacement of CINC-1 and NE from complexation with bronchio-epithelial 
HS/syndecan-1, dissipating the chemokine gradient for neutrophil flux across to the bronchial 
lumen. Following SM displacement of NE from shed HS/syndecan-1 in bronchial fluids, NE became 
accessible to inhibition by α1-antitrypsin endogenous in test samples. The antagonistic actions of SM 
against syndecan-1 binding of NE and CINC-1 in smoke-exposed airways suggest new therapeutic 
opportunities for modulating airway inflammation in smokers with SM delivery.
Chronic obstructive pulmonary disease (COPD) results from smoke-induced injury in the airways and 
the inflammatory response may become self-perpetuating even in the absence of ongoing stimuli1. A key 
component in the pathophysiological process of airway inflammation in COPD is neutrophilic inflam-
mation2. The vicious cycle of neutrophil influx and activation, release of neutrophil elastase (NE), and 
induction of further release of the chemokine interleukin 8 (IL-8) from activated bronchial epithelial cells 
and neutrophils reinforces an amplified, inflammatory cascade mechanism in smokers3,4. The binding 
of IL-85 and NE6,7 by heparan sulfate (HS)/syndecan-1 would prolong stability and sustain activities of 
these inflammatory mediator proteins. Targeting HS/syndecan-1 binding of these effectors in the airway 
environment could modulate smoking-related airway inflammation.
Immobilisation and dimerisation of IL-8 on HS/syndecan-15 that lined the endothelium and bron-
chial epithelium8 facilitated a chemokine gradient for neutrophil egress into the airway9. Elevated IL-8 
levels in sputum and bronchial epithelium of patients with COPD correlated with the extent of neutro-
philic inflammation and disease severity10–12.
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While shedding of syndecan-1 dissipated the chemokine gradient13, binding of shed syndecan-1 to NE 
upon neutrophil degranulation6,14 sustained the activity of NE. Although local production of secretory 
leucoprotease inhibitor15 can counteract NE activity, the local effect can be overwhelmed at bronchial 
sites where neutrophilic inflammation recurs. Alpha1-antitrypsin (α 1-AT), derived from not only hepat-
ocytes16 but also from lung epithelial cells and alveolar macrophages17 would then become the major 
anti-protease defense7. Despite adequate production of anti-NE in COPD, NE could still evade anti-NE 
action by association with de-condensed chromatin18 and shed syndecan6.
Heparin fragments of <10-mer can compete with endogenous HS/syndecan-1 for binding to IL-85 
and NE6. Clinical application of such anti-inflammatory actions, however, was limited by the potent 
anti-coagulant property with potential to cause haemorrhage19. That 2-O, 3-O-desulfated heparin showed 
minimal anti-coagulant activity but anti-protease and anti-inflammatory activities in a murine model of 
NE-induced airway inflammation20 added impetus to the pursuit of oligosaccharide alternatives.
In this study, we assessed BALF samples from smokers/ex-smokers with and without COPD for unop-
posed versus total NE burden and IL-8 and confirmed that findings were similarly observable in a rat 
model of smoking-induced lung inflammation. Sulfated-maltoheptaose (S-maltoheptaose) was tested as 
a heparin mimetic to target associations of airway NE and CINC-1 (the closest functional counterpart 
of human IL-8 in rats)21 with HS/syndecan-1. In smoke-exposed rats, airway delivery of S-maltoheptaose 
antagonized HS/syndecan-1 binding of NE and CINC-1 thus providing for dampened activities of the 
effectors in neutrophilic inflammation of the airways.
Results
Unopposed NE activity in BALF of COPD patients. The BALF of 42 subjects (28 with COPD 
and 14 non-COPD controls) were eligible for analysis; the difference in mean age between the two 
groups (COPD and non-COPD) were not statistically significant (P = 0.065) (Table  1). The levels of 
unopposed and total NE in BALF from COPD patients were significantly higher than those in subjects 
without COPD, irrelevant of smoking status (Fig. 1A). COPD patients had significantly higher NE levels 
compared to non-COPD subjects, and unopposed NE approximated that of total NE (Fig. 1A) despite 
the molar excesses of α 1-AT to unopposed NE at ratios averaging 8:1 (Fig. 1B). Among the non-COPD 
subjects, differences in total NE levels between the non-smokers and current smokers were statistically 
significant (P < 0.01) but differences in unopposed NE between these two groups of subjects were not 
(P = 0.137) (Fig.  1A). Western blots of BALF from COPD patients indicated co-localisation of NE, 
syndecan-1 and α 1-AT in the complex (nominal range of 90–250 kDa) while the corresponding casein 
zymogram reinforced occurrence of unopposed NE activity even though α 1-AT was associated with 
this complex (Fig. 1C). To confirm NE-syndecan interaction in the patient samples, we used a specific 
antibody against syndecan-1 for immunoprecipitation of the syndecan-NE complex from BAL samples 
of COPD patients. Analysis of the recovered immunoprecipitate by SDS-PAGE under reducing condition 
achieved dissociation of syndecan-1 from NE as revealed in the Western blot where NE-immunoreactivity 
was observable at the expected molecular size (29 kD) (Fig. 1D). The procedure was repeated with use 
of an irrelevant antibody, that against YFP, as negative control. Only a faint band was observable at the 
position corresponding to free NE (Fig. 1D). We therefore confirmed the occurrence of unopposed NE 
activity in syndecan-NE complexes found in BAL samples of COPD patients.
Unopposed NE activity in BALF of the smoke-exposed rat model. Following exposure to cig-
arette smoke, unopposed NE rose to as high a level as total NE in the BALF whereas the sham air con-





Number of subjects 14 28
Male Gender 14 28
Age (years) 62.4 ± 9.3 73.1 ± 5.5 P = 0.065
Smoking status
Current smokers 6 20
Ex-smokers 2 8
Non-smokers 6 0
FEV1% predicted 88.6 ± 10.0 62.4 ± 15.6 P < 0.01
FEV1/FVC 75.5 ± 3.7 52.5 ± 13.4 P < 0.01
Table 1.  Characteristics of subjects recruited. Data are presented as mean ± SD. COPD: chronic 
obstructive pulmonary disease; FEV1: forced expiratory volume in one second; FVC: forced vital capacity.
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Figure 1. NE is unopposed in BALF of patients with COPD. (A) BALF samples were assayed for 
NE levels, both total (by ELISA) and unopposed (by active site titration). COPD patients (current 
smokers, n = 20; ex-smokers, n = 8) indicated higher total and unopposed NE levels than the non-COPD 
controls (n = 14). In COPD, given the near equivalence of total NE and unopposed NE, NE in bronchial 
environment existed in forms unopposed by physiological anti-elastase. (B) These forms were unopposed 
despite eight times of the endogenous elastase inhibitor, α 1-AT. **P < 0.001, *P < 0.01. (C) Western blots 
of BALF of representative COPD patients (lanes 1 – 4) probed by antibodies against NE (a), syndecan-1 
(SDC-1), (b) and α 1-AT (c); corresponding casein zymogram of the BALF samples (d). (D) Specific 
antibody against syndecan for immunoprecipitation of the syndecan-NE complex from BALF samples of 
representative COPD patients, followed by SDS-PAGE in attempt to dissociate syndecan from NE and then 
immunoblotting assay with the same NE antibody again. Western blotting demonstrated unbound NE 
(dissociated from the syndecan-NE complex) at the expected band size of 29 kDa. Although the band width 
appeared to be a smear, the peak density corresponded to the expected band size at 29 kDa. Representative 
results from two BALF samples of COPD patients are shown.
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Smoking-induced unopposed NE was not due to inadequate supply of α 1-AT as shown by the excess 
of α1-AT to unopposed NE at molar ratios averaging 3:1 in the BALF of smoke-exposed rats (Fig. 2B).
Decrease in unopposed NE activity with S-maltoheptaose treatment. Following delivery 
of S-maltoheptaose to the airways of smoke-exposed rats, dose-dependent decrease in unopposed 
NE reached as low as 65% of the levels in smoke-exposed rats which were given blank carrier with-
out S-maltoheptaose (Fig.  3A). Total NE, however, remained at elevated levels, similar to those of 
smoke-exposed rats treated with blank carrier only (without S-maltoheptaose added). In the sham air 
group, both total and unopposed NE remained at basal levels with S-maltoheptaose treatment.
Western blot and zymographic analyses of BALF samples were performed to explore if S-maltoheptaose 
acted by displacement of NE from association with syndecan-containing complexes (Fig. 3B). In BALF 
of smoke-exposed rats treated with blank carrier only (without S-maltoheptaose), NE in co-localization 
with α 1-AT and syndecan-1 in the nominal range of 90–250 kD in the Western blot (Fig.  3B, Lanes 1 
in panels a – c) was found to be proteolytically active in the casein zymogram (Fig. 3B, Lane 1 in panel 
d). In the presence of NE-specific Eglin C tetrapeptide, the proteolytic activity was no longer detectable 
(Fig. 3B, Lane 2 in panel d) whereas associations of NE and α 1-AT with syndecan-1 persisted (Fig. 3B, 
Lanes 2 in panels a – c). In BALF of smoke-exposed rats treated with increasing dose of S-maltoheptaose, 
NE- and α 1-AT-immunopositivities extended into the (50–90 kD) region in the Western blot, beyond the 
syndecan-positive region (Fig. 3B, Lanes 3–5 in panels a and c). The corresponding (50–90 kD) regions of 
the casein zymogram indicated no proteolytic activity in contrast to residual proteolytic activity observ-
able in the (90–250 kD) regions (Fig. 3B, Lanes 3 – 5 in panel d).
Decreased neutrophil count and myeloperoxidase with S-maltoheptaose treatment. Following 
delivery of S-maltoheptaose to the airways of smoke-exposed rats, the rise in percentage of neutrophils 
in BALF over the sham air group (25.08 ± 0.77% vs 6.60 ± 0.84% respectively) was halved in the dose 
range tested. By contrast, percentage of neutrophils remained high in the smoke-exposed rats that were 
Figure 2. NE is unopposed in BALF of cigarette smoke-exposed rats. (A) Cigarette smoke-exposed rats 
(n = 8) indicated higher NE levels, both total and unopposed, than those of the sham air controls (n = 8). 
(B) These forms were unopposed despite three times of the endogenous inhibitor, α 1-AT. **P < 0.001.
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Figure 3. Dose-dependent decrease in unopposed NE with airway treatment of S-maltoheptaose.  
(A) Airway treatment of cigarette smoke-exposed rats (CS, n = 8) with S-maltoheptaose-on-chitosan 
carrier beads resulted in dose-dependent decrease in unopposed NE despite negligible change in total NE 
in BALF samples. NE levels of the sham air controls (SA, n = 8) are included for comparison. **P < 0.001, 
*P < 0.01. (B) Western blots of the BALF samples were performed for NE (a), syndecan-1 (SDC-1), (b) and 
α 1-AT (c); casein zymography of the BALF samples was performed in parallel (d). NE and α 1-AT remained 
co-localized with SDC-1 in the nominal range of 90–250 kD (Lanes 1 and 2 of each panel); this range 
indicated proteolytic activity (panel d, Lane 1) that was inhibited by treatment with Eglin C tetrapeptide 
(Panel d, Lane 2). In BALF samples of rats given airway treatment of S-maltoheptaose, NE- and α 1-AT-
immunopositivites extended beyond the SDC-positive region (Panels a–c, Lanes 3–5) in correlation with 
no proteolytic activity in the casein zymogram (Panel d, Lanes 3–5). When NE was displaced from SDC-1, 
it became accessible to inhibition by α 1-AT. Lanes 1: neat BALF; Lanes 2: Eglin c-treated BALF; Lanes 3–5: 
BALF from smoke-exposed rats treated respectively with 20 μ g, 100 μ g and 500 μ g of S-maltoheptaose on 
carrier beads via the airways.
sham air + neat 
chitosan
sham air + S-
maltohepatose-chitosan
cigarette smoke + neat 
chitosan
cigarette smoke + S-
maltohepatose-chitosan
Total cells (105/ml) 2.55 ± 0.13 2.80 ± 0.32 9.33 ± 0.43 6.23 ± 0.33
Neutrophils (%) 7.73 ± 0.22 6.98 ± 0.71 24.58 ± 0.75 13.53 ± 1.05
Eosinophils (%) 2.55 ± 0.13 2.90 ± 0.43 0.75 ± 0.13 1.50 ± 0.36
Lymphocytes (%) 24.53 ± 2.86 24.01 ± 4.35 3.73 ± 1.44 18.10 ± 3.34
Macrophages (%) 65.18 ± 2.73 66.11 ± 4.49 70.94 ± 0.70 60.64 ± 3.14
Protein (mg/ml) 0.14 ± 0.04 0.14 ± 0.02 1.08 ± 0.61 0.74 ± 0.05
Table 2.  Leucocyte counts and total protein concentration in BALF samples of smoke-exposed rats and 
sham air controls.
treated with blank carrier only (Table 2 and Fig. 4A). Neither treatment with S-maltoheptaose nor the 
blank carrier affected the inflammatory cell counts or percentage of neutrophils in the sham air group 
(Table 2 and Fig. 4A). Within the dose range of S-maltoheptaose tested, MPO activity in the BALF of 
smoke-exposed rats dropped by 20%, contrasting the elevated MPO activities among smoke-exposed rats 
treated with blank carrier or otherwise (Fig. 4B).
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Immunohistochemistry for neutrophils and CINC-1 in rat bronchial tissue. In contrast to the 
dense accumulation of neutrophils along the vascular endothelium adjacent to the basal side of the 
bronchial epithelium as shown by smoke-exposed rats treated with blank carrier (Fig.  5A, panel a), 
airway treatment with S-maltoheptaose resulted in marked reduction of neutrophils (Fig. 5A, panel c). 
The minimal neutrophils in airways of the sham air controls were unaffected by treatment with carrier, 
loaded with S-maltoheptaose or without (Fig. 5A, panel e).
In smoke-exposed rats treated with S-maltoheptaose, CINC-1 immuno-reactivity was weak on the 
luminal side and hardly detectable on the basal side (Fig.  5A, panel d). This contrasts with the dense 
CINC-1 immuno-reactivity along both luminal and basal sides of the bronchial epithelium as observable 
in smoke-exposed rats with blank carrier (Fig. 5A, panels b versus d). Double immunofluorescence fur-
ther revealed co-localisation of CINC-1 and syndecan-1 along the bronchial epithelium in the positive 
controls (Fig. 5B, panels c, e, g). Treatment with S-maltoheptaose resulted in barely detectable CINC-1 
immuno-reactivity whereas syndecan-1 immuno-reactivity remained detectable along the bronchial 
epithelium.
S-maltoheptaose selectively targeted the CINC-1 gradient. To verify that S-maltoheptaose per-
turbed the gradient of CINC-1 across the bronchial epithelium, lung tissue homogenates of smoke-exposed 
rats were monitored for change in CINC-1 level. The rise in CINC-1 level in the smoke-exposed rats 
above that of sham air controls (98.39 ± 17.25 pg/mg protein vs 41.02 ± 10.01 pg/mg protein, respec-
tively) was reduced by 50% following treatment with 20 μ g S-maltoheptaose (Fig. 6A). No further decline 
in CINC-1 level was seen with increase in S-maltoheptaose dose.
Figure 4. Neutrophil recruitment and degranulation into the bronchial lumen level off with airway 
treatment of S-maltoheptaose. Cigarette smoke-exposed rats (CS, n = 8) were given airway treatment of 
S-maltoheptaose-on-chitosan carrier beads at the doses indicated. The CS group showed significant increase 
in neutrophil count (A) and myeloperoxidase (MPO, neutrophil degranulation marker) (B) when compared 
with basal values of sham air controls (SA, n = 8). In both groups, the increase in basal levels of the SA 
group were unaffected by airway treatment with the carrier beads with or without loading of  
S-maltoheptaose. **P < 0.001.
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Among the smoke-exposed rats, the CINC-1 levels in BALF from sham-treated rats measured 
196.50 ± 20.63 ng/ml, whereas those following S-maltoheptaose treatment measured 265.00 ± 19.34 ng/
ml (n = 3 in each case, P < 0.01). Chemotactic response to CINC-1 in BALF samples of smoke-exposed 
and control rats were assessed with use of the Boyden chamber. The chemotactic index shown by neu-
trophils in response to recombinant CINC-1 in medium (10 ng/ml) was similar to that in response to 
smoke-exposed rat BALF. The chemotactic response to smoke-exposed rat BALF was suppressed maxi-
mally by 72% following neutralisation with a CINC-1-specific antibody at 50 ng/ml (Fig. 6B). In contrast, 
a non-specific antibody showed no neutralisation effect.
We also examined the smoke-exposed rat lung tissue homogenates for pro-inflammatory cytokines 
that do not bind HS moieties in the airways, such as TNF-α and IL-1β . The rise in TNF-α level in the 
smoke-exposed rats above that of the sham air group (871.74 ± 99.84 pg/mg protein vs 433.54 ± 93.15 pg/
mg protein) was maintained following treatment with S-maltoheptaose within the dose range tested 
(Fig.  6C). Similarly, the rise in IL-1β level in smoke-exposed rats over that of the sham air group 
(278.27 ± 54.11 pg/mg protein vs 149.31 ± 46.98 pg/mg protein) was maintained following the same dose 
range of S-maltoheptaose treatment (Fig. 6D).
Figure 5. Decrease in airway accumulation of neutrophils and CINC-1 following treatment with S-
maltoheptaose. (A) Lung tissue sections were stained for NE (a, c, e) or CINC-1 (b, d, f) and then counter-
stained with haematoxylin. NE-positive cells lining the basal side of the bronchial epithelium were rarely 
observed in cases treated with S-maltoheptaose (a vs c, arrows). CINC-1 immuno-positivity enriched along 
the luminal and basal sides of the bronchial epithelium were barely observable in cases treated with S-
maltoheptaose (b vs d, arrowheads). Neither immuno-positivity for NE nor CINC-1 was observable in the 
sham air controls (e & f). (B) Double immunofluorescence for syndecan-1 (SDC-1) and CINC-1. (a) and 
(b): Bright field images of the lung tissue sections. Tissues treated with mere carrier revealed localisation of 
SDC-1 (c) and CINC-1 (e) to the bronchial epithelium, more prominent on the luminal side than on the 
basal side. The merged image (g) further revealed co-localisation of SDC-1 and CINC-1. Tissue sections 
treated with S-maltoheptaose indicated weaker immunofluorescence for SDC-1 (d) and hardly any detectable 
CINC-1 (f) at the bronchial epithelium. This was reinforced by the sole immunofluorescence of SDC-1 at 
the bronchial epithelium in the merged image (h). Arrows in (g) indicate sites where SDC-1 and CINC-1 are 
co-localised at the luminal side of the bronchial epithelium. *bronchial lumen. Scale bar = 100 μ m.
www.nature.com/scientificreports/
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Discussion
In the BALF of COPD subjects and of smoke-exposed rats, we demonstrated unopposed NE activity 
in the presence of an excess of α 1-AT. In both cases, association of NE with HS/syndecan-1 precluded 
inhibition of NE activity by the prevailing α 1-AT. The delivery of S-maltoheptaose to the airways of 
smoke-exposed rats could compete out NE and CINC-1 from associations with HS/syndecan-1.
The unopposed NE was high in BALF from smokers with COPD compared to non-smokers or smok-
ers without COPD. The results reflected perpetuation of neutrophil extravasation and degranulation in 
the airway environment even after cessation of smoking in COPD. These results are consistent with 
previous findings in both longitudinal22 and cross-sectional studies23,24 that elevations in neutrophils and 
IL-8 in sputum persisted in ex-smokers with COPD. Such unopposed or excessive NE activities have 
also been reported in ex-smokers with subclinical emphysema12. Recurrent airway exposure to cigarette 
smoke induces pro-inflammatory cytokines such as IL-1β and TNF-α , which in turn induce a chemokine 
gradient25. We have previously demonstrated in bronchiectasis that syndecan-binding of NE in sputum 
sol was responsible for limiting access to NE by prevailing α 1-AT, resulting in high unopposed NE 
activity6,7. We speculate that in COPD, the smoke-induced airway remodeling has progressed to support 
a chemokine gradient which sustains egress of neutrophils into the airways and allows NE activity that 
evades opposition by α 1-AT. Here in this work we confirmed that in the BALF of COPD subjects, NE 
existed in syndecan-bound forms that fail to be opposed by α 1-AT.
Our choice of S-maltoheptaose26 is based on preliminary finding of in vitro efficacy of the sulfated 
malto-oligosaccharide series in displacement of NE from the syndecan complex in BALF of COPD sub-
jects, increasing up the series from maltose to maltoheptaose. In the rat model, airway treatment with 
S-maltoheptaose not only displaced NE from binding to syndecan-1 complexes in the bronchial lumen, 
but also facilitated encounters of displaced NE with prevailing α 1-AT to effect inhibition of NE activity. 
The decrease in unopposed NE observed in BALF after S-maltoheptaose treatment was dose-dependent 
Figure 6. CINC-1 but neither TNF-α nor IL-1β in lung homogenates levels off following treatment with 
S-maltoheptaose. Cigarette smoke-exposed rats (CS, n = 8) and sham air controls (SA, n = 8) were given 
airway treatment of S-maltoheptaose-on-chitosan carrier beads at the doses indicated. The levels of CINC-1 
(A), TNF-α (C) and IL-1β (D) in lung homogenates were determined with ELISA. The CS group showed 
significant increase in the three cytokines when compared with basal levels in lung homogenates of the SA 
group. The increase in CINC-1 was lowered to the 50th-percentile level with treatment of S-maltoheptaose 
but the increase in TNF-α and IL-1β were maintained. Basal levels of the SA group were unaffected by 
airway treatment with the carrier beads with or without loading of S-maltoheptaose. (B) BALF samples of 
both CS and SA groups were subjected to Boyden chamber assay for neutrophil chemotactic activity due 
to CINC-1. The chemotactic index of the CS group was significantly higher than that of the SA group. 
Pretreatment of the CS sample with an antibody against CINC-1 at 50 ng/ml maximally neutralized 72% of 
the neutrophil chemotactic index. **P < 0.001.
www.nature.com/scientificreports/
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but the post-treatment levels did not reach basal levels, indicating the potential for dose adjustment or 
titration to levels that can prevent tissue destruction yet preserve innate immunity due to NE activity. 
These results suggest the need for further experiments with temporal spacing of doses, and evaluation of 
functional outcomes with lung function tests.
In the smoke-exposed rats, the rise in neutrophils in BALF was reduced despite increased doses of 
S-maltoheptaose, implying a low dose of S-maltoheptaose was sufficient for curbing neutrophil recruit-
ment to the inflamed airways. Like NE, MPO is released from azurophilic granules of neutrophils upon 
neutrophil degranulation in COPD27. Dissimilar to NE, however, MPO activity was not confounded 
by binding to HS moieties of shed proteoglycans28. MPO activity in the BALF of smoke-exposed rats 
dropped by 20% with delivery of S-maltoheptaose, reflecting curbed recruitment of neutrophils to the 
airways at a low dose of S-maltoheptaose.
Airway treatment with S-maltoheptaose resulted in marked reduction of neutrophils along the basal 
side of the bronchial epithelium; together with the weak CINC-1 immuno-reactivity on the luminal 
side in smoke-exposed rat, these suggested the disruption of neutrophil extravasation into the airways 
with S-maltoheptaose treatment. These results supported that CINC-1 is a target molecule displaced 
from bronchio-epithelial syndecan-1 by S-maltoheptaose. As shown in the Boyden chamber experiments, 
the chemotactic response to smoke-exposed rat BALF was suppressed to a large extent by more than 
70% following neutralisation with a CINC-1-specific antibody, supporting the role of rat CINC-1 as a 
major chemokine that recruited neutrophils to the bronchial epithelium of smoke-exposed rats. The 
maintained rise in TNF-α and IL-1β level in the smoke-exposed rats above that of the sham air group 
even after treatment with S-maltoheptaose within the dose range tested (Figs.  6C,D) supported that 
S-maltoheptaose targeted HS-binding effectors like NE and CINC-1 during neutrophilic inflammation 
in the bronchial environment.
Recent studies have demonstrated the importance of HS moieties of cell surface syndecan-1 in bind-
ing to chemokines and in establishing a chemotactic gradient which guides neutrophil extravasation 
to the inflamed airway29. Binding to HS moieties can protect IL-8 from proteolytic attack and thus 
prolong the half-life of the chemokine in the inflamed airways30. Airway delivery of IL-8 mutated in 
the HS binding domain led to decreased accumulation of the chemokine and neutrophils in lung tis-
sue of otherwise healthy animals31,32. We exploited the concept that sulfated oligosaccharides of 6- to 
10-mer are heparin mimetics that can compete with tissue HS moieties for binding of IL-833 and thus 
can abolish the gradient of inflammatory chemokines. Taking advantage of the defined molecular size 
and negative charge of S-maltoheptaose for ready loading onto carrier chitosan beads by electrostatic 
attraction and its predictable affinities for HS-binding inflammatory effectors in airway environments, we 
showed that airway treatment of smoke-exposed rats with a low dose of S-maltoheptaose was sufficient 
to decrease neutrophil count and MPO level in BALF. The same low dose of S-maltoheptaose was suffi-
cient to decrease CINC-1 in smoke-exposed rat lung tissue homogenate. Immunohistochemical staining 
indicated de-localisation of CINC-1 from the syndecan-1-positive lining of bronchial epithelium. Our 
results reinforce not only the importance of HS moieties in the inflamed airway tissue in maintaining 
the neutrophil chemotactic gradient but also suggest a strategy for dissipation of the aberrant chemokine 
buildup at HS moieties of the affected airway environment.
Other than S-maltoheptaose, synthetic heparin oligosaccharides can be synthesized with limited 
anti-factor Xa and anti-factor IIa activities20,34,35 and these could as well be exploited to target HS-binding 
effectors of neutrophilic inflammation. Sulfated linked cyclitols26 that are defined in molecular size and 
charge have also been designed to inhibit protein/HS interactions. Given a listing of these synthetic hep-
arin mimetics according to affinities for HS-binding inflammatory effectors and preclinical indications of 
efficacy, informed selection of heparin mimetic(s) for treatment of aberrant neutrophilia and unopposed 
NE in the COPD airway environment will be possible20.
It is noteworthy that the short duration and passive tobacco smoke exposure in the rat model may not 
be the same as chronic tobacco smoking in human smokers. However, we did observe similar patterns of 
unopposed NE burden in relation to prevailing anti-protease in the BALF of COPD and the rat model.
In conclusion, we demonstrated that recurrent cigarette smoke exposure induced neutrophil accumu-
lation and unopposed NE activity despite excess anti-protease activity in the rat airways, similar to that 
found in the airways of current and ex-smokers with COPD. S-maltoheptaose instilled into the airways 
of this rat model could compete out IL-8 and NE from respective associations with immobilised and shed 
forms of HS/syndecan-1, reducing neutrophil chemotaxis across the bronchial epithelium and rendering 
NE susceptible to inhibition by anti-protease. The animal data provides proof-of-concept for a possible 
strategy for treatment of chronic airway diseases in which NE activity is persistently dominant despite 
adequate anti-protease activity.
Materials and Methods
Subjects. The study protocol was approved by the Institutional Review Board of the Hong Kong 
University/Hong Kong Hospital Authority Hong Kong West Cluster (IRB UW 11-085). All clinical pro-
cedures were performed in accordance with approved regulations and guidelines. Successive subjects 
undergoing bronchoscopy in the Department of Medicine, Queen Mary Hospital, Hong Kong, were 
recruited. Recruited subjects were recorded, as current smokers, ex-smokers, or non-smokers. Written 
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informed consent for collection of a sample of BALF for research was obtained prior to diagnostic bron-
choscopy. Spirometry was performed according to the ATS/ERS criteria. The severity of airflow obstruc-
tion was classified according to GOLD Statement (www.goldcopd.com). Patients in acute exacerbation 
of COPD were excluded from bronchoscopy. BALF samples collected from subjects with endobronchial 
tumor or lesions, active pneumonia, asthma and bronchiectasis were excluded. BALF collections from 
smokers, ex-smokers and non-smokers who did not have evidence of airflow obstruction on spirometry 
served as controls.
Lung function tests and collection of BALF from COPD subjects. The lung function tests 
included spirometric tests of forced vital capacity (FVC) and forced expiratory volume in one second 
(FEV1). Spirometry measurements were done using a Sensor-Medics V22d Pulmonary Function Lab 
System (SensorMedics, Yorba Linda, CA, USA). Bronchoalveolar lavage fluid (BALF) was collected 
from COPD subjects in a sub-segmental bronchus during bronchoscopy by instillation and aspiration 
of 150 ml sterile and pyrogen free phosphate buffered saline. To minimise cell contamination from the 
upper airways, the recovered BALF fluid was centrifuged at 200 g for 10 min at 4 °C. The supernatant was 
concentrated ten times with the use of Amicon Ultra-15 centrifugal filter Unit (Millipore, Billerica, MA, 
USA) at 400 g for 15 min. The concentrate was then divided into aliquots for storage at − 80 °C until use.
Preparation of chitosan beads and loading with sulfated maltoheptaose. S-maltoheptaose 
was prepared as described before36 and loading of chitosan beads with S-maltoheptaose was prepared as 
follows: Five-micron (5 μ m) chitosan beads were prepared with use of SPG membrane emulsification37. 
Briefly, chitosan (1.6%) was prepared in a solution containing 1% (w/v) acetic acid and 5% (w/v) sodium 
chloride. The chitosan solution (2 ml) (aqueous phase) was forced (at 16 kPa) through 5-μ m pores of the 
SPG membrane into the oil phase containing 4% (w/v) Tween® 80, with stirring of the W/O emulsion 
at 600 rpm for 2 hours. Chitosan beads that formed in the W/O emulsion were solidified by addition of a 
mixture made up of 100 μ l of 10 M NaOH, 100 μ l of Tween® 80 and 4 ml of mineral oil. Chitosan beads 
were washed with 1% Tween 80 (x2) and then distilled water (x3). After air-drying, the chitosan beads 
were stored under dessication at 24 °C.
In preparation for use, the chitosan beads (50 mg) were re-suspended in 1 ml of PBS (pH 5.8) con-
taining 1 mg/ml of sulfated maltoheptaose at 24 °C for 16 hours. The mixture was centrifuged (15,000 g, 
2 min) and then 0.1 ml of the supernatant was sampled to assay for the sulfated maltoheptaose that 
remained in the supernatant with use of CPC turbidimetry38. Sulfated maltoheptaose that was loaded 
onto the chitosan beads was determined by the difference between the total sulfated maltoheptaose 
added to the suspension of chitosan beads and that which remained in the supernatant after the 16-hour 
incubation.
Airway delivery of S-maltoheptaose to smoke-exposed rats. Sprague-Dawley rats (200 g body 
weight) were divided into groups of twelve: (i) smoke-exposed rats (exposed to 4% cigarette smoke: 
Camel brand; filter, R.J. Reynolds, Winston-Salem, NC, USA), one hour/day for 30 days, in a venti-
lated smoking-chamber39; (ii) sham air control rats inhaled room air. Under pentobarbitone anesthesia 
(60 mg/kg body weight; intraperitoneal), six rats in each group were given intra-tracheal administration 
of S-maltoheptaose (20 – 500 μ g)-loaded chitosan beads (2 mg) via an insufflator device (PennCentury 
Inc., Philadelphia, Pennsylvania, USA). The other six rats in each group received neat chitosan beads 
(2 mg) as vehicle control. After recovery from anaesthesia, rats accessed food and water ad lib until sac-
rifice 72 hours later under pentobarbitone overdose. BALF and lung tissues were collected for analysis. 
All procedures were in strict accordance with the NIH Guide for the care and use of laboratory animal 
and approved by the Committee on Use of Live Animals for Teaching and Research, LKS Faculty of 
Medicine, The University of Hong Kong.
Assay for unopposed NE concentration in BALF. The unopposed NE activities, expressed as 
molar ratios both to total NE and to α 1-antitrypsin as determined by ELISA, were assayed in BALF 
of COPD patients and non-COPD controls, and in BALF of smoke-exposed rats compared to sham 
air controls, before and after airway administration of S-maltoheptaose. The unopposed NE activ-
ities was determined spectrophotometically by using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as 
substrate at 2 mM in 0.2 M Tris-HCl, 0.5 M NaCl, pH 8.0; hydrolytic release of p-nitroaniline was 
followed spectrophotometrically at 410 nm, 37 °C (E410 = 8800). To determine the equivalent molar-
ity of active NE, the rate of p‐nitrophenol production from the samples was monitored and reference 
to that of equivalent activity of purified NE (Merck Millipore, Germany), of which the active con-
centration have been titrated with increasing known concentrations of the NE irreversible inhibitor, 
methoxysuccinyl-l-alanyll-alanyl-prolyl-l-valyl-chloromethylketone. The minimum concentration of the 
inhibitor that can completely inhibit the activities gave the active site concentration of the purified NE7.
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Assay for total NE concentration in BALF. NE was measured with a sandwich enzyme-linked 
immunosorbent assay (ELISA) kit (Hycult Biotech, The Netherlands) according to the manufacturer’s 
instructions.
Assay for MPO Activity in BALF. Myeloperoxidase (MPO) activity of BALF was assayed spectro-
photometrically using 0.0005% hydrogen peroxide as substrate in 50 mmol/L phosphate buffer contain-
ing 0.167 mg/ml o-dianisidine dihydrochloride at pH 7.0. The change in absorbance at 460 nm, 37 °C was 
measured using a spectrophotometer. The MPO activity was then determined by reference to commercial 
available MPO (Merck KGaA, Darmstadt, Germany) which had been standardized by active site titration. 
One unit of MPO activity was defined as that degrading 1 μ mole of peroxide per minute at 37 °C. Data 
were expressed as mole per unit gram of protein.
Assay for α1-AT concentration in BALF. Sandwich enzyme-linked immunosorbent assay (ELISA) 
for α 1-AT level in BALF was performed with goat anti-human α 1-AT (Sigma-Aldrich, St. Louis, MO, 
USA) immobilised in the wells of microtitre plates. Non-specific binding was blocked with 3% bovine 
serum albumin. Known dilutions of BALF were applied at 100 μ l/well and incubated (1 h, 37 °C) to 
allow α 1-AT capture. The captured antigen was incubated (1 h, 37 °C) in turn with the primary anti-
body, rabbit anti-human α 1-AT (diluted 1:400, Roche Diagnostics, Mannheim, Germany) (50 μ l), sec-
ondary antibody, goat anti-rabbit IgG conjugated with peroxidase (diluted 1:1000; Roche Diagnostics, 
Mannheim, Germany) (50 μ l) and the substrate (o-phenylenediamine, Sigma-Aldrich, St. Louis, MO, 
USA) for color development. Wells were washed with PBS-Tween 20 between incubations. Absorbance 
at 490 nm was read with a microplate reader (Molecular Devices Corporation, Sunnyvale, CA, USA). 
Assays were performed in duplicate. The standard curve was prepared with serial dilutions of reference 
α 1-AT (human placenta; Sigma-Aldrich, St. Louis, MO, USA). Data were expressed as mole per unit 
gram of protein.
Western blot analysis of rat BALF. BALF of rats were subjected to sodium dodecyl sulfate polyacryla-
mide gel electrophoresis (SDS-PAGE) in a 10% gel under non-reducing condition and electro-blotted 
onto polyvinylidene fluoride membrane. Non-specific binding was blocked with 5% nonfat dry milk (1 h, 
24°C) before the blot was probed for the epitope of interest. Primary antibodies used were those against 
α 1-AT (diluted 1:200, rabbit anti-human α 1-AT; Sigma-Aldrich, St. Louis, MO, USA), NE (diluted 1:200, 
mouse anti-human NE, Dako, CA, USA), syndecan-1 (diluted 1:200, goat anti-mouse syndecan, Serotec, 
Raleigh, NC, USA) and secondary antibodies were conjugated with horseradish peroxidase. The mem-
branes were washed with PBS-Tween 20 between incubations. Visualisation was enhanced with a chemi-
luminescence kit (ECL; Amersham Biosciences, Piscataway, NJ, USA). Bound antibodies were stripped 
from the membrane by incubation (30 min, 50°C) with 100 mM 2-mercaptoethanol, 2% sodium dodecyl 
sulfate, 62.5 mM Tris-HCl, pH 6.7, before re-probing with another primary antibody.
Co-immunoprecipitation. BALF samples (total protein, 300 μ g per sample) of COPD patients were 
pre-cleared with use of protein A-agarose beads (Invitrogen). The supernatant was incubated (16 h, 4 °C) 
with rabbit anti-syndecan-1 (1 μ g; Invitrogen) (test) or rabbit anti-YFP (BD Biosciences (control), on 
a rota-mixer. A 50% slurry (30 μ l) of proteinA-agarose beads was incubated (3 h, 4 °C) to recover the 
immunoprecipitate in the mixture. After 3 washes with Tris-buffered saline containing 0.1% Tween-20, 
the beads were heated in reducing sample buffer (10 min, 100 °C) to elute the samples in preparation for 
SDS-PAGE and Western blotting.
Casein zymography. Casein zymography of BALF was performed in a 10% PAGE gel containing 
1 mg/ml casein under non-reducing condition at 4 °C. After electrophoresis, the gel was washed twice 
(15 min each) in 2.5% Triton X-100 to remove the SDS. The gel was washed with distilled water several 
times and then incubated in zymography developing buffer (50 mM Tris–HCl, 200 mM NaCl, 0.02% 
NaN3, pH 7.6) at 37°C for 18 hours. The gel was stained for protein with Coomassie Blue R-250 (0.5% 
in 40% methanol and 10% acetic acid) and then de-stained in the solvent. Non-staining regions of the 
gel indicated caseinolytic activity.
Total and differential cell counts in rat BALF. Bronchoalveolar lavage (BAL) was performed with 
1 ml of sterile phosphate-buffered saline. The collected BAL fluid was centrifuged at 200 g for 10 min-
utes at 4°C. The supernatants were stored at − 80 °C and the cell pellets were resuspended/diluted to a 
concentration of 2 × 105 cells/ml. The cell suspension (0.2 ml) was then spun at 1000 rpm for 5 minutes 
onto a poly-L-lysine-coated glass slide with use of a Cytospin 2 cytocentrifuge (Shandon Instruments, 
Sewickley, PA, USA). The slides were air-dried, fixed and then stained with Trypan Blue or May–Giemsa 
stain. Total and differential cell counts of the cytocentrifuge preparations were performed under the 
microscope with the aid of an eyepiece graticule.
Immunohistochemical analysis of rat lung section. The largest lobe of the left lung from each 
animal was excised and then fixed in 4% (w/v) paraformaldehyde, dehydrated with ethanol and embed-
ded in paraffin. The resulting tissue blocks were microtome-sectioned (Leica) to a thickness of 5 μ m and 
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then mounted on SuperFrost® glass slides (Menzel-Glaeser, Braunschweig, Germany). The slides were 
de-waxed, rehydrated and then stained with primary antibody against NE (diluted 1:200, goat anti-NE, 
Calbiochem, Gibbstown, NJ, USA) or CINC-1 (diluted 1:200, goat anti-CINC, Abcam, Cambridge, 
MA, USA). This was followed by incubation with HRP-conjugated rabbit anti-goat IgG (diluted 1:100 
Serotec, Raleigh, NC, USA). Visualization of the immunohistochemical signals was enhanced with a 
Dako EnVision + System- HRP (DAB) kit (Dako, Carpinteria, CA, USA). The preparations were counter-
stained with haematoxylin (Vector Laboratories, Burlingame, CA, USA) and then permanently mounted 
(BioMeda, Foster City, CA, USA). Images were captured with use of the Olympic IX70 microscope 
system.
For double immunofluorescence analysis, the slides were de-waxed, rehydrated and stained with 
primary antibody against syndecan-1 (diluted 1:200, rabbit anti-syndecan-1, Invitrogen, Carlsbad, CA, 
USA) and CINC-1 (diluted 1:200, goat anti-CINC, Abcam, Cambridge, MA, USA). This was followed 
by incubation with Donkey anti goat Alex Flour 594 (diluted 1:500, Invitrogen, Carlsbad, CA, USA) and 
goat anti-rabbit Alex Flour 488 (diluted 1:500, Invitrogen, Carlsbad, CA, USA). Images were viewed and 
captured with use of the Olympic IX70 microscope system.
ELISA for cytokines and chemokines. TNF-α , IL-1β and CINC-1 protein concentrations in rat lung 
homogenates were measured using the rat DuoSet® ELISA Development kits (R&D Systems, MN, USA). 
The lower detection limits for TNF-α , IL-1β and CINC-1 were 62.5, 31.25 and 4.7 pg/ml respectively.
Chemotaxis Assay. Both human and rat neutrophils were similarly assessed for chemotactic response 
to CINC-1 in BALF collected from cigarette smoke exposed rats and sham air controls, a 48-well modi-
fied Boyden chamber (Neuroprobe, Gaithersburg, MD, USA) was used as described previously40. A total 
of 2 × 105 neutrophils (from peripheral blood of healthy controls) in a volume of 50 μ l were added in 
the top wells of the chamber. The bottom wells contained 30 μ l of the samples to be assayed for chem-
otactic activity. Samples included recombinant rat CINC-1 (R&D Systems, Minneapolis, MN, USA) in 
RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA), BALF from smoke-exposed rats and BALF from 
sham air controls. After incubation of the setup in a CO2 incubator (with humidified air with 5% CO2, 
37 °C) for 1 hour, the setup was disassembled to recover the filters. The filters were rinsed with PBS to 
remove surface-lying non-migrating neutrophils. Neutrophils that remained attached to the underside of 
the filters were fixed with methanol and then stained with Diff-Quick (Fisher Scientific, Pittsburgh, PA, 
USA). The filters were then mounted onto a glass slide and stained neutrophils were counted under the 
Olympus IX70 microscope with the aid of an eyepiece graticule. The chemotactic index was expressed 
as the number of neutrophils that migrated toward a test sample relative to the number of neutrophils 
that migrated towards a medium control.
Statistical analysis. Data were expressed as mean ± SD. The INSTAT and PRISM statistical software 
packages (GraphPad, Inc., San Diego, CA, USA) were used. Data were analysed by one-way analysis of 
variance (ANOVA) with a Bonferroni’s post hoc test or Mann-Whitney U test. Differences are considered 
statistically significant when P < 0.05.
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